Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479057 | 1.00 | CRBN (0.41) | CRBNDDB1IKZF3ADRA1DADRA1A | |
| SCHEMBL25031304 | 0.90 | CRBN (0.38) | CRBNDDB1IKZF3ADRA1DADRA1A | |
| SCHEMBL30479076 | 0.90 | CRBN (0.38) | CRBNDDB1IKZF3ADRA1DADRA1A | |
| SCHEMBL27224949 | 0.89 | CRBN (0.41) | CRBNDDB1IKZF3ADRA1DADRA1A | |
| SCHEMBL25031312 | 0.88 | CRBN (0.36) | CRBNDDB1IKZF3ADRA1DADRA1A | |
| SCHEMBL27224955 | 0.88 | CRBN (0.39) | CRBNDDB1IKZF3ADRA1DADRA1A | |
| SCHEMBL25332537 | 0.88 | CRBN (0.38) | CRBNDDB1IKZF3ADRA1DADRA1A | |
| SCHEMBL25823256 | 0.87 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL30475505 | 0.87 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL30965602 | 0.84 | CRBN (0.38) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885IKZF3 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.